<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Stroke</journal-id><journal-id journal-id-type="iso-abbrev">J Stroke</journal-id><journal-id journal-id-type="publisher-id">JOS</journal-id><journal-title-group><journal-title>Journal of Stroke</journal-title></journal-title-group><issn pub-type="ppub">2287-6391</issn><issn pub-type="epub">2287-6405</issn><publisher><publisher-name>Korean Stroke Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26846760</article-id><article-id pub-id-type="pmc">4747071</article-id><article-id pub-id-type="doi">10.5853/jos.2015.01578</article-id><article-id pub-id-type="publisher-id">jos-2015-01578</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect and Safety of Rosuvastatin in Acute Ischemic Stroke</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Heo</surname><given-names>Ji Hoe</given-names></name><xref ref-type="corresp" rid="c1-jos-2015-01578"/><xref ref-type="aff" rid="af1-jos-2015-01578"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Dongbeom</given-names></name><xref ref-type="aff" rid="af1-jos-2015-01578"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nam</surname><given-names>Hyo Suk</given-names></name><xref ref-type="aff" rid="af1-jos-2015-01578"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Eung Yeop</given-names></name><xref ref-type="aff" rid="af2-jos-2015-01578"><sup>b</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Young Dae</given-names></name><xref ref-type="aff" rid="af1-jos-2015-01578"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Kyung-Yul</given-names></name><xref ref-type="aff" rid="af3-jos-2015-01578"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ki-Jeong</given-names></name><xref ref-type="aff" rid="af1-jos-2015-01578"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Joonsang</given-names></name><xref ref-type="aff" rid="af1-jos-2015-01578"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Youn Nam</given-names></name><xref ref-type="aff" rid="af4-jos-2015-01578"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Byung Chul</given-names></name><xref ref-type="aff" rid="af5-jos-2015-01578"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Byung-Woo</given-names></name><xref ref-type="aff" rid="af6-jos-2015-01578"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jong S.</given-names></name><xref ref-type="aff" rid="af7-jos-2015-01578"><sup>g</sup></xref></contrib><contrib contrib-type="author"><collab>EUREKA Investigators</collab></contrib><aff id="af1-jos-2015-01578"><label>a</label>Department of Neurology, Yonsei University College of Medicine, Seoul, <country>Korea</country></aff><aff id="af2-jos-2015-01578"><label>b</label>Department of Radiology, Gachon University, Gil Medical Center, Incheon, <country>Korea</country></aff><aff id="af3-jos-2015-01578"><label>c</label>Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, <country>Korea</country></aff><aff id="af4-jos-2015-01578"><label>d</label>Clinical Trials Center, Severance Hospital, Yonsei University Health System, Seoul, <country>Korea</country></aff><aff id="af5-jos-2015-01578"><label>e</label>Department of Neurology, Hallym University Sacred Heart Hospital, Pyeongchon, <country>Korea</country></aff><aff id="af6-jos-2015-01578"><label>f</label>Department of Neurology, Seoul National University College of Medicine, Seoul, <country>Korea</country></aff><aff id="af7-jos-2015-01578"><label>g</label>Department of Neurology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, <country>Korea</country></aff></contrib-group><author-notes><corresp id="c1-jos-2015-01578">Correspondence: Ji Hoe Heo&#x02003; Department of Neurology, Yonsei University College of Medicine 50-1 Yonsei-ro, Seodaemoon-gu, Seoul 03722, Korea&#x02003; Tel: +82-2-2228-1605 Fax: +82-2-393-0705 E-mail: <email>jhheo@yuhs.ac</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>29</day><month>1</month><year>2016</year></pub-date><volume>18</volume><issue>1</issue><fpage>87</fpage><lpage>95</lpage><history><date date-type="received"><day>26</day><month>10</month><year>2015</year></date><date date-type="rev-recd"><day>6</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>6</day><month>1</month><year>2016</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2016 Korean Stroke Society</copyright-statement><copyright-year>2016</copyright-year><license><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background and Purpose</title><p>The benefit of statins in acute stroke remains uncertain. Statins may prevent stroke recurrence during the acute stage of stroke via pleiotropic effects. However, statins may increase the risk of intracerebral hemorrhage. We investigated the effect and safety of rosuvastatin in acute stroke patients.</p></sec><sec><title>Methods</title><p>This randomized, double-blind, multi-center trial compared rosuvastatin 20 mg and placebo in statin-na&#x000ef;ve stroke patients who underwent diffusion-weighted imaging (DWI) within 48 hours after symptom onset. The primary outcome was occurrence of new ischemic lesions on DWI at 5 or 14 days.</p></sec><sec><title>Results</title><p>This trial was stopped early after randomization of 316 patients due to slow enrollment. Among 289 patients with at least one follow-up imaging, the frequency of new ischemic lesions on DWI was not different between groups (rosuvastatin: 27/137, 19.7% vs. placebo: 36/152, 23.6%) (relative risk 0.83, 95% confidence interval 0.53&#x02013;1.30). Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2&#x000b1;1.0 mm<sup>3</sup> vs. placebo: 0.3&#x000b1;1.3 mm<sup>3</sup>; <italic>P</italic>=0.784) was not different, either. However, hemorrhagic infarction or parenchymal/subarachnoid hemorrhage on gradient-recalled echo magnetic resonance imaging occurred less frequently in the rosuvastatin group (6/137, 4.4%) than the placebo group (22/152, 14.5%, <italic>P</italic>=0.007). Among 314 patients with at least one dose of study medication, progression or clinical recurrence of stroke tended to occur less frequently in the rosuvastatin group (1/155, 0.6% vs. 7/159, 4.4%, <italic>P</italic>=0.067). Adverse events did not differ between groups.</p></sec><sec><title>Conclusions</title><p>The efficacy of rosuvastatin in reducing recurrence in acute stroke was inconclusive. However, statin use was safe and reduced hemorrhagic transformation.</p></sec></abstract><kwd-group><kwd>Stroke</kwd><kwd>Rosuvastatin</kwd><kwd>Statin</kwd><kwd>Diffusion-weighted imaging</kwd></kwd-group><funding-group><award-group><funding-source country="KR">Ministry of Health and Welfare</funding-source><award-id>HI08C2149</award-id><award-id>HI10C2020</award-id></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Statins are effective in primary and secondary prevention of stroke [<xref rid="b1-jos-2015-01578" ref-type="bibr">1</xref>-<xref rid="b3-jos-2015-01578" ref-type="bibr">3</xref>]. Their long-term beneficial effects may be primarily mediated by their lipid-lowering effects. Statins may also work effectively in preventing recurrence or progression during the acute stage of stroke because they have antithrombotic, anti-inflammatory, and anti-oxidative effects [<xref rid="b4-jos-2015-01578" ref-type="bibr">4</xref>-<xref rid="b7-jos-2015-01578" ref-type="bibr">7</xref>].</p><p>Several observational studies have suggested that statin use before or during the acute stage of stroke was associated with better functional outcome and reduced mortality [<xref rid="b7-jos-2015-01578" ref-type="bibr">7</xref>-<xref rid="b9-jos-2015-01578" ref-type="bibr">9</xref>]. By contrast, intracerebral hemorrhage (ICH) developed more frequently in patients treated with high-dose statins during the subacute or chronic stage of ischemic stroke in large randomized trials [<xref rid="b2-jos-2015-01578" ref-type="bibr">2</xref>,<xref rid="b10-jos-2015-01578" ref-type="bibr">10</xref>]. Since the risk of hemorrhagic transformation is greater during the acute stage of stroke, statin treatment in acute stroke raises the concern of increased ICH risk. However, data from randomized trials are insufficient to establish whether statins are effective and safe in patients with acute ischemic stroke [<xref rid="b11-jos-2015-01578" ref-type="bibr">11</xref>]. Furthermore, statins are not recommended in stroke guidelines as an agent with neuroprotective actions to improve outcome in acute stroke [<xref rid="b12-jos-2015-01578" ref-type="bibr">12</xref>]. Therefore, we investigated the effect and safety of rosuvastatin in acute ischemic stroke patients.</p></sec><sec sec-type="methods"><title>Methods</title><p>This double-blind, placebo-controlled, randomized, multicenter study was approved by the Ministry of Food and Drug Safety, Korea, and the institutional review board at each study center. Written informed consent was obtained from each patient. This trial (Effects of very early use of rosuvastatin in preventing recurrence of ischemic stroke [EUREKA]) was registered on ClinicalTrials.gov (NCT01364220).</p><sec><title>Study population</title><p>We enrolled patients over 20 years old diagnosed with acute ischemic stroke on diffusion-weighted imaging (DWI) within 48 hours after symptom onset who had been untreated with a statin for the previous 3 months. Patients also should show any degree of stenosis on the relevant artery of infarction on DWI. Patients with hemorrhagic stroke, history of symptomatic hemorrhagic stroke, high-risk cardiac sources of embolism, or stroke of other determined etiology were excluded. Other exclusion criteria are described in <xref ref-type="supplementary-material" rid="SD1">Supplementary data</xref>.</p><p>The modified intention-to-treat population consisted of patients who underwent a baseline magnetic resonance imaging (MRI), had triglyceride (TG) &#x0003c; 500 mg/dL, low-density lipoprotein cholesterol &#x0003c; 190 mg/dL, and took at least one dose of study medication. The per-protocol (PP) population consisted of patients who completed scheduled MRIs without a major protocol violation.</p></sec><sec><title>Randomization, blinding, and interventions</title><p>Patients were randomized 1:1 to receive either rosuvastatin or placebo. Permutated-block randomization with a block size of 4 was generated by an independent clinical trials center (Severance Hospital, Yonsei University Health System, Seoul, Korea). After patients were screened and completed enrollment, drugs were assigned a unique study number, selected sequentially from the central randomization list that corresponded to the treatment pack, and allocated in a double-blind manner. The drug was administered within 18 hours after baseline MRI and then daily during the 14-day treatment period. Patients received either one 20-mg tablet or a placebo tablet, once daily.</p></sec><sec><title>Sample size</title><p>We hypothesized that, compared to placebo, rosuvastatin would reduce the occurrence of new ischemic lesions on MRI by 30%. To test our hypothesis, assuming a type I error of 5% and a power of 80%, sample sizes were calculated as 260 in each group. The proportion in the rosuvastatin group was assumed to be 0.40 under the null hypothesis and 0.28 under the alternative hypothesis, based on a previous study that recognized new ischemic lesions on DWI in 34%-47.4% of patients during the first week after baseline DWI taken within 24 hours after symptom onset [<xref rid="b13-jos-2015-01578" ref-type="bibr">13</xref>,<xref rid="b14-jos-2015-01578" ref-type="bibr">14</xref>]. The test statistic used was the 2-sided Fisher&#x02019;s exact test. Assuming a drop-out rate of 5%, the total number of patients needed was 547.</p></sec><sec><title>Imaging protocol</title><p>To be eligible, patients underwent DWI, fluid attenuated inversion recovery, gradient-recalled echo (GRE), and magnetic resonance (MR) angiography that included both the circle of Willis and neck vessels at baseline using a 1.5 T or 3.0 T MR scanner. Computed tomography (CT) angiography was also allowed. The follow-up imaging schedule included DWI, GRE, and fluid attenuated inversion recovery at 5 &#x000b1; 1 days and 14 &#x000b1; 2 days using the same MR scanner. The images were saved in Digital Imaging and Communications in Medicine (DICOM) format and sent to the independent clinical trials center for review of adequacy and analyses.</p></sec><sec><title>Adjudication of images</title><p>Two stroke neurologists blinded to clinical and group information reviewed angiographic images and determined the presence of relevant artery stenosis in ischemic lesions on DWI. In cases of discrepancy between the reviewers, the decision was made by a third reviewer (a neuroradiologist). The reviewers also measured the degree of stenosis of the relevant artery based on methods used in the North American Symptomatic Carotid Endarterectomy Trial for extracranial arteries and the Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis trial for intracranial arteries [<xref rid="b15-jos-2015-01578" ref-type="bibr">15</xref>,<xref rid="b16-jos-2015-01578" ref-type="bibr">16</xref>] and categorized stenosis as &#x02265; 50% or &#x0003c; 50%.</p></sec><sec><title>Outcomes</title><p>Imaging outcomes were assessed by 2 reviewers blinded to clinical and group information. The primary outcome was occurrence of a new ischemic lesion on DWI or fluid attenuated inversion recovery at 5 or 14 days. The secondary outcomes were the volume change of ischemic lesions and the percent improvement in National Institute of Health Stroke Scale (NIHSS) at 5 days and 14 days. The safety outcome included adverse events, laboratory results, and the presence of any intracranial hemorrhagic transformation on GRE, which included hemorrhagic infarction (HI) and parenchymal hemorrhage based on European Cooperative Acute Stroke Study definitions [<xref rid="b17-jos-2015-01578" ref-type="bibr">17</xref>]. In case of a discrepancy in the presence of new lesions or hemorrhagic transformation, conclusions were reached by consensus. The volume of infarctions was measured on DWI in a semi-automatic manner using Xelis software (Infinitt, Seoul, Korea). The intraclass correlation coefficient between the reviewers for log-transformed volume measurements was 0.99. The percent improvement was defined as ([NIHSS at 5 days or 14 days &#x02013; NIHSS at baseline]/NIHSS at baseline) &#x000d7; 100 [<xref rid="b18-jos-2015-01578" ref-type="bibr">18</xref>].</p><p>Details of the conduction of study are provided in <xref ref-type="supplementary-material" rid="SD1">Supplemental data</xref>.</p></sec><sec><title>Statistical analysis</title><p>The efficacy outcome was compared based on the modified intention-to-treat and PP population. Safety was assessed in all patients who took at least one dose of study medication. We used the &#x003c7;<sup>2</sup> test with continuity correction to compare the occurrence of newly developed DWI lesion, the independent sample t test to compare the percent improvement in NIHSS, and the mixed-effect model to compare the change in log-transformed DWI lesion volume between the rosuvastatin and placebo groups. The &#x003c7;<sup>2</sup> test or Fisher&#x02019;s exact test was performed to compare safety outcomes. Statistical analyses were performed using SAS statistical software, version 9.2 (SAS institute Inc., Cary, NC). Data are presented as number (%) or mean &#x000b1; standard deviation. Two-sided <italic>P</italic> values &#x0003c; 0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Baseline characteristics</title><p>A total of 28 centers in Korea participated in this study, and 25 centers enrolled at least 1 patient. Among 318 patients enrolled, 316 patients met inclusion criteria and were randomized, and 314 took at least one dose of study medication (155 in the rosuvastatin group and 159 in the placebo group). Among them, the primary outcome was assessed in 289 patients (<xref rid="f1-jos-2015-01578" ref-type="fig">Figure 1</xref>). Baseline demographic characteristics were similar between the groups except total cholesterol and low-density lipoprotein cholesterol levels, which were higher in the rosuvastatin group (<xref rid="t1-jos-2015-01578" ref-type="table">Table 1</xref>, <xref ref-type="supplementary-material" rid="SD1">Supplemental Table 1</xref>). Characteristics of the patients whose primary outcome was not assessed are provided in as a <xref ref-type="supplementary-material" rid="SD1">Supplemental Table 2</xref>.</p></sec><sec><title>Efficacy outcomes</title><p>Efficacy was compared in the modified intention-to-treat population (137 patients in the rosuvastatin group and 152 patients in the placebo group). New ischemic lesions on DWI were observed less frequently in the rosuvastatin group (27 patients [19.7%]) than in the placebo group (36 patients [23.6%]), but the difference was not statistically significant (absolute difference 3.9%, relative risk [RR] 0.83, 95% confidence interval [CI] 0.53-1.30, <italic>P</italic>=0.500) (<xref rid="f2-jos-2015-01578" ref-type="fig">Figure 2A</xref>). Infarction volumes on DWI increased at 5 days and then decreased at 14 days in both groups. Infarct volume growth at 5 days (log-transformed volume change, rosuvastatin: 0.2 &#x000b1; 1.0 mm<sup>3</sup> vs. placebo: 0.3 &#x000b1; 1.3 mm<sup>3</sup>; <italic>P</italic>=0.784) and percent improvement in NIHSS (rosuvastatin vs. placebo: 36.6 &#x000b1; 56.7 vs. 27.1 &#x000b1; 90.8 at 5 days, <italic>P</italic>=0.282 and 51.4 &#x000b1; 51.6 vs. 42.7 &#x000b1; 91.5 at 14 days, <italic>P</italic>=0.315) were not different.</p></sec><sec><title>Safety outcomes</title><p>Of 314 patients, 3 in the placebo group (1.9%) and none in the rosuvastatin group demonstrated clinical recurrence of ischemic stroke (<italic>P</italic>=0.248). Progression or clinical recurrence of stroke was reported as a serious adverse event in 7 patients (4.4%) in the placebo group, but in only 1 patient (0.6%) in the rosuvastatin group (<italic>P</italic>=0.067). The frequency of adverse events did not differ between the groups (<xref rid="t2-jos-2015-01578" ref-type="table">Table 2</xref>).</p><p>On GRE, HI was observed in 6 patients at baseline (5/155 [3.2%] in the rosuvastatin and 1/159 [0.65] in the placebo groups). Occurrence of any new intracranial hemorrhagic transformation (HI, parenchymal hemorrhage, or subarachnoid hemorrhage) or aggravation of pre-existing HI1 at base-line (defined as conversion to HI2 or parenchymal hemorrhage) was assessed in 289 patients with available GRE at 5 or 14 days. Any new HI was observed less frequently in the rosuvastatin group (6/137, 4.4%) than in the placebo group (22/152, 14.5%) (<italic>P</italic>=0.007). In the rosuvastatin group, 1 patient developed parenchymal hemorrhage (<italic>P</italic>=0.478), and 1 patient developed focal cortical subarachnoid hemorrhage on GRE (<italic>P</italic>=0.478), both of whom were asymptomatic (<xref rid="t3-jos-2015-01578" ref-type="table">Table 3</xref>).</p></sec><sec><title>Post-hoc subgroup analysis</title><p>We compared the occurrence of a new ischemic lesion on DWI in patients with relevant artery stenosis &#x02265; 50%. New ischemic lesions were found in 19 of 83 patients (22.9%) in the rosuvastatin group and 25 of 87 patients (28.7%) in the placebo group (RR, 0.80; 95% CI, 0.48-1.33; <italic>P</italic>=0.387). Twenty of 78 patients (25.6%) in the rosuvastatin group and 26 of 80 patients (32.5%) in the placebo group with multiple lesions on baseline DWI had new lesions (RR, 0.79; 95% CI, 0.48-1.29; <italic>P</italic>=0.346) (<xref rid="f2-jos-2015-01578" ref-type="fig">Figure 2A</xref>).</p></sec><sec><title>PP Population</title><p>A total of 118 patients in the rosuvastatin group and 129 patients in the placebo group were included for the PP population (<xref rid="f1-jos-2015-01578" ref-type="fig">Figure 1</xref>). New ischemic lesions were found in 24 patients (20.3%) in the rosuvastatin group and 34 patients (26.3%) in the placebo group (RR 0.77; 95% CI, 0.49-1.22, <italic>P</italic>=0.335) (<xref rid="f2-jos-2015-01578" ref-type="fig">Figure 2B</xref>). In the subgroup with relevant artery stenosis &#x02265; 50%, new ischemic lesions were detected in 17 of 79 patients (21.5%) in the rosuvastatin group and 24 of 78 patients (30.8%) in the placebo group (RR, 0.70; 95% CI 0.41&#x02013;1.20; <italic>P</italic>=0.192). In the subgroup with multiple lesions, new ischemic lesions were observed in 17 of 69 (24.8%) patients in the rosuvastatin group and 25 of 69 (36.2%) patients in the placebo group (RR 0.68; 95% CI, 0.41&#x02013;1.14; <italic>P</italic>=0.145) (<xref rid="f2-jos-2015-01578" ref-type="fig">Figure 2B</xref>).</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><p>This study was inconclusive to prove the hypothesis that rosuvastatin may effectively reduce early recurrence of new ischemic lesions, probably due to insufficient sample size. We could not include a sufficient number of patients because of slow enrollment. Despite insufficient evidence that use of a statin is effective or safe in acute ischemic stroke, investigators were reluctant to administer placebo, since statin use on discharge became a performance measure for primary stroke center certification [<xref rid="b19-jos-2015-01578" ref-type="bibr">19</xref>]. However, a non-significant trend for less frequent appearance of new ischemic lesions on DWI or progression or clinical recurrence of stroke was observed in the rosuvastatin group. Thus, our findings support previous observational studies showing a benefit of statins in the acute stage of stroke [<xref rid="b7-jos-2015-01578" ref-type="bibr">7</xref>,<xref rid="b8-jos-2015-01578" ref-type="bibr">8</xref>].</p><p>Previous randomized trials using statins in acute stroke included small numbers of patients and showed no clinical effect or even worse outcomes after statin treatment [<xref rid="b20-jos-2015-01578" ref-type="bibr">20</xref>-<xref rid="b22-jos-2015-01578" ref-type="bibr">22</xref>]. Serial MRIs were used to determine outcomes in this study. Defining clinical recurrence of stroke is sometimes difficult during the acute stage because pre-existing symptoms often fluctuate or progress. Many ischemic lesions that are recognized on DWI during the acute stage of stroke are clinically silent, but they are direct surrogate markers of recurrence. Ischemic injury progresses during the acute stage of infarctions [<xref rid="b23-jos-2015-01578" ref-type="bibr">23</xref>] and may cause growth of infarct volume. By using MRI surrogate markers such as DWI and GRE, subclinical occurrence of ischemic and expansion of ischemic lesions as well as hemorrhagic outcomes might be assessed accurately.</p><p>In this study, new ischemic lesions in the placebo group developed less often than expectation which was assumed based on previous reports [<xref rid="b13-jos-2015-01578" ref-type="bibr">13</xref>,<xref rid="b14-jos-2015-01578" ref-type="bibr">14</xref>]. This might be partly ascribed to the high frequency of use with dual or triple antiplatelet agents (about 75%) in this study population. We hypothesized that the use of statins could reduce the risk of early recurrence of either symptomatic or asymptomatic ischemic lesions and expansion of ischemic lesions in acute stroke. This was because antithrombotic and anti-inflammatory effects of statins have been demonstrated in many experimental studies. Statins also play a beneficial role in stabilizing atherosclerotic plaques [<xref rid="b6-jos-2015-01578" ref-type="bibr">6</xref>,<xref rid="b24-jos-2015-01578" ref-type="bibr">24</xref>]. In the subgroup analysis of our trial, the RR reduction of new DWI lesion occurrence in the rosuvastatin group was greater in patients who were more likely to have had an atherothrombotic infarction, such as a 20% reduction in patients with relevant artery stenosis &#x02265; 50% and 21% reduction in those with multiple lesions in the territory of relevant artery stenosis. In the PP population (excluding patients without relevant artery stenosis after assessment), the difference was much greater. Although it is possible that statins are more effective in the prevention of stroke with an atherothrombotic mechanism, this hypothesis was inconclusive in our study.</p><p>In this study, rosuvastatin 20 mg was safe in that there were no differences in the development of adverse events. Notably, the occurrence of HI on GRE was remarkably reduced in the rosuvastatin group. In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial, atorvastatin 80 mg increased the risk of ICH (hazard ratio, 1.68; 95% CI 1.09-2.59) [<xref rid="b2-jos-2015-01578" ref-type="bibr">2</xref>], and in the Heart Protection Study, simvastatin 40 mg was associated with approximately 2-fold increased risk of ICH in patients with prior stroke [<xref rid="b10-jos-2015-01578" ref-type="bibr">10</xref>]. However, statin use was not associated with ICH in a large cohort study in patients with recent ischemic stroke [<xref rid="b25-jos-2015-01578" ref-type="bibr">25</xref>], and in a meta-analysis of primary and secondary prevention studies of statins [<xref rid="b26-jos-2015-01578" ref-type="bibr">26</xref>,<xref rid="b27-jos-2015-01578" ref-type="bibr">27</xref>]. Our findings suggest that statin use in the acute stage of stroke may protect against microvascular (capillary) damage and prevent HI. Matrix metalloproteinase-9 is a key proteinase that mediates HI by disrupting microvascular integrity [<xref rid="b28-jos-2015-01578" ref-type="bibr">28</xref>]. Statins reduce expression of matrix metalloproteinase-9 in endothelial cells, astrocytes, and human plasma [<xref rid="b29-jos-2015-01578" ref-type="bibr">29</xref>,<xref rid="b30-jos-2015-01578" ref-type="bibr">30</xref>]. Thus, the protective effect of statins against occurrence of HI might be in part mediated by inhibiting matrix metalloproteinase-9.</p><p>This study has several limitations. First, this study did not include patients with cardioembolic sources and was conducted in one Asian country. Therefore, our results should be interpreted with caution. Second, the median NIHSS of the study population at screening was 3, which suggests that enrolled patients had rather milder stroke. Although we assessed the outcome in the subgroup with significant stenosis of the relevant artery, this might affect the outcome such as the frequency of progression or recurrence of stroke. Furthermore, the primary outcome of this trial was not clinical stroke recurrence, but imaging-based recurrent ischemic lesions. As a result, the data of clinical stroke recurrence was captured based on the investigators&#x02019; reports of adverse events. Finally, this study was stopped early due to slow enrollment, which resulted in underpowered results.</p><p>In conclusion, by using MRI surrogate markers such as DWI and GRE, subclinical occurrence of ischemic as well as hemorrhagic outcomes may be assessed very sensitively and accurately with a relatively smaller sample size. Further studies are required to elucidate the potential benefit of statins in acute stroke patients to conclusively support the routine use of statins.</p></sec></body><back><ack><p>Steering Committee: Ji Hoe Heo (Principle investigator, Chair), Dae Ryong Kang , Eung Yeop Kim, Jong S. Kim, Young Dae Kim, Byung Chul Lee, Kyung-Yul Lee, Hyo Suk Nam, Byung-Woo Yoon. Data Safety and Monitoring Board: Min Soo Park (Chair), Chung Mo Nam, Seung-Koo Lee, Kwang Ho Lee. Imaging Review and Adjudication: Dongbeom Song (Chair), Eung Yeop Kim, Jinna Kim, Eun-Hye Kim, Ki-Jeong Lee, Joonsang Yoo. Statistical Analysis: Youn Nam Kim. Enrolling Sites and Investigators: Severance Hospital: Ji Hoe Heo, Dong Hyun Lee, Jinkwon Kim, Tae-Jin Song; Samsung Changwon Hospital: Myoung-Jin Cha, Kyoung-Soo Lee; Kyung Hee University Hospital: Dae-Il Chang; Yeungnam University Medical Center: Jun Lee; Ewha Womans University Hospital: Yong-Jae Kim; Chunnam National University Hospital: Ki-Hyun Cho, Man-Seok Park, Joon-Tae Kim; Kangdong Hospital: Hye-Yeon Choi; Wonju Severance Hospital: Seo Hyun Km, Ji-Yong Lee; Sanggye Paik Hospital: Sang Won Han, Jae Hyeon Park; Changwon Fatima Hospital: Yo Han Jung, Jay-Cheol Kwon; Dongsan Medical Center: Sung-Il Sohn, Kyung-Hee Cho; Sacred Heart Hospital: Byung-Chul Lee, Mi Sun Oh; Samsung Medical Center: Oh Young Bang, Geyong-Moon Kim; Inha University Hospital: Joung-Ho Rha; Seoul National University Hospital: Byung-Woo Yoon; Pusan Paik Hospital: Eung Gyu Kim; Hangang Sacred Heart Hospital: Yang Ki Minn; Gangnam Severance Hospital: Kyung-Yul Lee; Asan Medical Center: Jong S. Kim; Chosun University Hospital: Seong Hwan Ahn; National Medical Center: Jong Yun Lee; Konyang University Hospital: Kee Ook Lee; Korea University Hospital: Woo-Keun Seo; Yeouido St. Mary&#x02019;s Hospital: A-Hyun Cho; Pusan National University Hospital: Han-Jin Cho.</p></ack><fn-group><fn fn-type="supported-by"><p>This trial was supported by a research grant from AstraZeneca and the Korea Healthcare Technology R&#x00026;D Project, Ministry of Health and Welfare, Republic of Korea (HI08C2149, HI10C2020). The investigators are fully responsible for the design of the study and protocol; conduct of the study; collection, monitoring, management, analyses, and interpretation of data; and writing and submission of the manuscript, without involvement of the sponsors.</p></fn><fn fn-type="conflict"><p>The authors have no financial conflicts of interest.</p></fn></fn-group><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>SUPPLEMENTARY DATA</label><media mimetype="image" mime-subtype="pdf" xlink:href="jos-2015-01578-supple1.pdf" orientation="portrait" id="d36e614" position="anchor"/></supplementary-material></sec><ref-list><title>References</title><ref id="b1-jos-2015-01578"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baigent</surname><given-names>C</given-names></name><name><surname>Keech</surname><given-names>A</given-names></name><name><surname>Kearney</surname><given-names>PM</given-names></name><name><surname>Blackwell</surname><given-names>L</given-names></name><name><surname>Buck</surname><given-names>G</given-names></name><name><surname>Pollicino</surname><given-names>C</given-names></name><etal/><collab>Cholesterol Treatment Trialists&#x02019; (CTT) Collaborators</collab></person-group><article-title>Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1267</fpage><lpage>1278</lpage><pub-id pub-id-type="pmid">16214597</pub-id></element-citation></ref><ref id="b2-jos-2015-01578"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amarenco</surname><given-names>P</given-names></name><name><surname>Bogousslavsky</surname><given-names>J</given-names></name><name><surname>Callahan</surname><given-names>A</given-names><suffix>3rd</suffix></name><name><surname>Goldstein</surname><given-names>LB</given-names></name><name><surname>Hennerici</surname><given-names>M</given-names></name><name><surname>Rudolph</surname><given-names>AE</given-names></name><etal/></person-group><article-title>High-dose atorvastatin after stroke or transient ischemic attack</article-title><source>N Engl J Med</source><year>2006</year><volume>355</volume><fpage>549</fpage><lpage>559</lpage><pub-id pub-id-type="pmid">16899775</pub-id></element-citation></ref><ref id="b3-jos-2015-01578"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tziomalos</surname><given-names>K</given-names></name><name><surname>Giampatzis</surname><given-names>V</given-names></name><name><surname>Bouziana</surname><given-names>SD</given-names></name><name><surname>Spanou</surname><given-names>M</given-names></name><name><surname>Kostaki</surname><given-names>S</given-names></name><name><surname>Papadopoulou</surname><given-names>M</given-names></name><etal/></person-group><article-title>Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke</article-title><source>Atherosclerosis</source><year>2015</year><volume>243</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">26355807</pub-id></element-citation></ref><ref id="b4-jos-2015-01578"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourcier</surname><given-names>T</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2000</year><volume>20</volume><fpage>556</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">10669656</pub-id></element-citation></ref><ref id="b5-jos-2015-01578"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sch&#x000e4;fer</surname><given-names>A</given-names></name><name><surname>Fraccarollo</surname><given-names>D</given-names></name><name><surname>Eigenthaler</surname><given-names>M</given-names></name><name><surname>Tas</surname><given-names>P</given-names></name><name><surname>Firnschild</surname><given-names>A</given-names></name><name><surname>Frantz</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rosuvastatin reduces platelet activation in heart failure: role of NO bioavailability</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2005</year><volume>25</volume><fpage>1071</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">15761193</pub-id></element-citation></ref><ref id="b6-jos-2015-01578"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sukhova</surname><given-names>GK</given-names></name><name><surname>Williams</surname><given-names>JK</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><article-title>Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2002</year><volume>22</volume><fpage>1452</fpage><lpage>1458</lpage><pub-id pub-id-type="pmid">12231565</pub-id></element-citation></ref><ref id="b7-jos-2015-01578"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>N&#x000ed; Chr&#x000f3;in&#x000ed;n</surname><given-names>D</given-names></name><name><surname>Asplund</surname><given-names>K</given-names></name><name><surname>&#x000c5;sberg</surname><given-names>S</given-names></name><name><surname>Callaly</surname><given-names>E</given-names></name><name><surname>Cuadrado-Godia</surname><given-names>E</given-names></name><name><surname>D&#x000ed;ez-Tejedor</surname><given-names>E</given-names></name><etal/></person-group><article-title>Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>448</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">23287777</pub-id></element-citation></ref><ref id="b8-jos-2015-01578"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biffi</surname><given-names>A</given-names></name><name><surname>Devan</surname><given-names>WJ</given-names></name><name><surname>Anderson</surname><given-names>CD</given-names></name><name><surname>Cortellini</surname><given-names>L</given-names></name><name><surname>Furie</surname><given-names>KL</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><etal/></person-group><article-title>Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>1314</fpage><lpage>1319</lpage><pub-id pub-id-type="pmid">21415396</pub-id></element-citation></ref><ref id="b9-jos-2015-01578"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>KS</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name></person-group><article-title>Statins in acute ischemic stroke: a systematic review</article-title><source>J Stroke</source><year>2015</year><volume>17</volume><fpage>282</fpage><lpage>301</lpage><pub-id pub-id-type="pmid">26437994</pub-id></element-citation></ref><ref id="b10-jos-2015-01578"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collins</surname><given-names>R</given-names></name><name><surname>Armitage</surname><given-names>J</given-names></name><name><surname>Parish</surname><given-names>S</given-names></name><name><surname>Sleight</surname><given-names>P</given-names></name><name><surname>Peto</surname><given-names>R</given-names></name><collab>Heart Protection Study Collaborative Group</collab></person-group><article-title>Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions</article-title><source>Lancet</source><year>2004</year><volume>363</volume><fpage>757</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">15016485</pub-id></element-citation></ref><ref id="b11-jos-2015-01578"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Squizzato</surname><given-names>A</given-names></name><name><surname>Romualdi</surname><given-names>E</given-names></name><name><surname>Dentali</surname><given-names>F</given-names></name><name><surname>Ageno</surname><given-names>W</given-names></name></person-group><article-title>Statins for acute ischemic stroke</article-title><source>Cochrane Database Syst Rev</source><year>2011</year><volume>8</volume><fpage>CD007551</fpage><pub-id pub-id-type="pmid">21833959</pub-id></element-citation></ref><ref id="b12-jos-2015-01578"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jauch</surname><given-names>EC</given-names></name><name><surname>Saver</surname><given-names>JL</given-names></name><name><surname>Adams</surname><given-names>HP</given-names><suffix>Jr</suffix></name><name><surname>Bruno</surname><given-names>A</given-names></name><name><surname>Connors</surname><given-names>JJ</given-names></name><name><surname>Demaerschalk</surname><given-names>BM</given-names></name><etal/></person-group><article-title>Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2013</year><volume>44</volume><fpage>870</fpage><lpage>947</lpage><pub-id pub-id-type="pmid">23370205</pub-id></element-citation></ref><ref id="b13-jos-2015-01578"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DW</given-names></name><name><surname>Latour</surname><given-names>LL</given-names></name><name><surname>Chalela</surname><given-names>JA</given-names></name><name><surname>Dambrosia</surname><given-names>J</given-names></name><name><surname>Warach</surname><given-names>S</given-names></name></person-group><article-title>Early ischemic lesion recurrence within a week after acute ischemic stroke</article-title><source>Ann Neurol</source><year>2003</year><volume>54</volume><fpage>66</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">12838521</pub-id></element-citation></ref><ref id="b14-jos-2015-01578"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>DW</given-names></name><name><surname>Kwon</surname><given-names>SU</given-names></name><name><surname>Yoo</surname><given-names>SH</given-names></name><name><surname>Kwon</surname><given-names>KY</given-names></name><name><surname>Choi</surname><given-names>CG</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Early recurrent ischemic lesions on diffusion-weighted imaging in symptomatic intracranial atherosclerosis</article-title><source>Arch Neurol</source><year>2007</year><volume>64</volume><fpage>50</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">17210808</pub-id></element-citation></ref><ref id="b15-jos-2015-01578"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chimowitz</surname><given-names>MI</given-names></name><name><surname>Lynn</surname><given-names>MJ</given-names></name><name><surname>Howlett-Smith</surname><given-names>H</given-names></name><name><surname>Stern</surname><given-names>BJ</given-names></name><name><surname>Hertzberg</surname><given-names>VS</given-names></name><name><surname>Frankel</surname><given-names>MR</given-names></name><etal/></person-group><article-title>Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis</article-title><source>N Engl J Med</source><year>2005</year><volume>352</volume><fpage>1305</fpage><lpage>1316</lpage><pub-id pub-id-type="pmid">15800226</pub-id></element-citation></ref><ref id="b16-jos-2015-01578"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson</surname><given-names>GG</given-names></name><name><surname>Eliasziw</surname><given-names>M</given-names></name><name><surname>Barr</surname><given-names>HW</given-names></name><name><surname>Clagett</surname><given-names>GP</given-names></name><name><surname>Barnes</surname><given-names>RW</given-names></name><name><surname>Wallace</surname><given-names>MC</given-names></name><etal/></person-group><article-title>The North American Symptomatic Carotid Endarterectomy Trial: surgical results in 1415 patients</article-title><source>Stroke</source><year>1999</year><volume>30</volume><fpage>1751</fpage><lpage>1758</lpage><pub-id pub-id-type="pmid">10471419</pub-id></element-citation></ref><ref id="b17-jos-2015-01578"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hacke</surname><given-names>W</given-names></name><name><surname>Kaste</surname><given-names>M</given-names></name><name><surname>Fieschi</surname><given-names>C</given-names></name><name><surname>Toni</surname><given-names>D</given-names></name><name><surname>Lesaffre</surname><given-names>E</given-names></name><name><surname>von Kummer</surname><given-names>R</given-names></name><etal/></person-group><article-title>Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)</article-title><source>JAMA</source><year>1995</year><volume>274</volume><fpage>1017</fpage><lpage>1025</lpage><pub-id pub-id-type="pmid">7563451</pub-id></element-citation></ref><ref id="b18-jos-2015-01578"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nam</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><name><surname>Han</surname><given-names>SW</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>JY</given-names></name><name><surname>Ahn</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Prediction of long-term outcome by percent improvement after the first day of thrombolytic treatment in stroke patients</article-title><source>J Neurol Sci</source><year>2009</year><volume>281</volume><fpage>69</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">19304298</pub-id></element-citation></ref><ref id="b19-jos-2015-01578"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gorelick</surname><given-names>PB</given-names></name></person-group><article-title>Primary and comprehensive stroke centers: history, value and certification criteria</article-title><source>J Stroke</source><year>2013</year><volume>15</volume><fpage>78</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">24324943</pub-id></element-citation></ref><ref id="b20-jos-2015-01578"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kennedy</surname><given-names>J</given-names></name><name><surname>Hill</surname><given-names>MD</given-names></name><name><surname>Ryckborst</surname><given-names>KJ</given-names></name><name><surname>Eliasziw</surname><given-names>M</given-names></name><name><surname>Demchuk</surname><given-names>AM</given-names></name><name><surname>Buchan</surname><given-names>AM</given-names></name><collab>FASTER Investigators</collab></person-group><article-title>Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial</article-title><source>Lancet Neurol</source><year>2007</year><volume>6</volume><fpage>961</fpage><lpage>969</lpage><pub-id pub-id-type="pmid">17931979</pub-id></element-citation></ref><ref id="b21-jos-2015-01578"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beer</surname><given-names>C</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Bynevelt</surname><given-names>M</given-names></name><name><surname>Hankey</surname><given-names>GJ</given-names></name><name><surname>Puddey</surname><given-names>IB</given-names></name></person-group><article-title>A randomized placebo controlled trial of early treatment of acute ischemic stroke with atorvastatin and irbesartan</article-title><source>Int J Stroke</source><year>2012</year><volume>7</volume><fpage>104</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">22044557</pub-id></element-citation></ref><ref id="b22-jos-2015-01578"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montaner</surname><given-names>J</given-names></name><name><surname>Chac&#x000f3;n</surname><given-names>P</given-names></name><name><surname>Krupinski</surname><given-names>J</given-names></name><name><surname>Rubio</surname><given-names>F</given-names></name><name><surname>Mill&#x000e1;n</surname><given-names>M</given-names></name><name><surname>Molina</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial</article-title><source>Eur J Neurol</source><year>2008</year><volume>15</volume><fpage>82</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">18070096</pub-id></element-citation></ref><ref id="b23-jos-2015-01578"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iadecola</surname><given-names>C</given-names></name><name><surname>Anrather</surname><given-names>J</given-names></name></person-group><article-title>The immunology of stroke: from mechanisms to translation</article-title><source>Nat Med</source><year>2011</year><volume>17</volume><fpage>796</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">21738161</pub-id></element-citation></ref><ref id="b24-jos-2015-01578"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aikawa</surname><given-names>M</given-names></name><name><surname>Voglic</surname><given-names>SJ</given-names></name><name><surname>Sugiyama</surname><given-names>S</given-names></name><name><surname>Rabkin</surname><given-names>E</given-names></name><name><surname>Taubman</surname><given-names>MB</given-names></name><name><surname>Fallon</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Dietary lipid lowering reduces tissue factor expression in rabbit atheroma</article-title><source>Circulation</source><year>1999</year><volume>100</volume><fpage>1215</fpage><lpage>1222</lpage><pub-id pub-id-type="pmid">10484543</pub-id></element-citation></ref><ref id="b25-jos-2015-01578"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hackam</surname><given-names>DG</given-names></name><name><surname>Austin</surname><given-names>PC</given-names></name><name><surname>Huang</surname><given-names>A</given-names></name><name><surname>Juurlink</surname><given-names>DN</given-names></name><name><surname>Mamdani</surname><given-names>MM</given-names></name><name><surname>Paterson</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Statins and intracerebral hemorrhage: a retrospective cohort study</article-title><source>Arch Neurol</source><year>2012</year><volume>69</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21911657</pub-id></element-citation></ref><ref id="b26-jos-2015-01578"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McKinney</surname><given-names>JS</given-names></name><name><surname>Kostis</surname><given-names>WJ</given-names></name></person-group><article-title>Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials</article-title><source>Stroke</source><year>2012</year><volume>43</volume><fpage>2149</fpage><lpage>2156</lpage><pub-id pub-id-type="pmid">22588266</pub-id></element-citation></ref><ref id="b27-jos-2015-01578"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Everett</surname><given-names>BM</given-names></name><name><surname>Mora</surname><given-names>S</given-names></name><name><surname>Glynn</surname><given-names>RJ</given-names></name><name><surname>MacFadyen</surname><given-names>J</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name></person-group><article-title>Safety profile of subjects treated to very low low-density lipoprotein cholesterol levels (&#x0003c;30 mg/dl) with rosuvastatin 20 mg daily (from JUPITER)</article-title><source>Am J Cardiol</source><year>2014</year><volume>114</volume><fpage>1682</fpage><lpage>1689</lpage><pub-id pub-id-type="pmid">25439449</pub-id></element-citation></ref><ref id="b28-jos-2015-01578"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heo</surname><given-names>JH</given-names></name><name><surname>Lucero</surname><given-names>J</given-names></name><name><surname>Abumiya</surname><given-names>T</given-names></name><name><surname>Koziol</surname><given-names>JA</given-names></name><name><surname>Copeland</surname><given-names>BR</given-names></name><name><surname>del Zoppo</surname><given-names>GJ</given-names></name></person-group><article-title>Matrix metalloproteinases increase very early during experimental focal cerebral ischemia</article-title><source>J Cereb Blood Flow Metab</source><year>1999</year><volume>19</volume><fpage>624</fpage><lpage>633</lpage><pub-id pub-id-type="pmid">10366192</pub-id></element-citation></ref><ref id="b29-jos-2015-01578"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sapienza</surname><given-names>P</given-names></name><name><surname>Borrelli</surname><given-names>V</given-names></name><name><surname>Sterpetti</surname><given-names>AV</given-names></name><name><surname>Dinicola</surname><given-names>S</given-names></name><name><surname>Tartaglia</surname><given-names>E</given-names></name><name><surname>di Marzo</surname><given-names>L</given-names></name></person-group><article-title>Dose-dependent effect of rosuvastatin in the regulation of metalloproteinase expression</article-title><source>Ann Vasc Surg</source><year>2011</year><volume>25</volume><fpage>823</fpage><lpage>829</lpage><pub-id pub-id-type="pmid">21620672</pub-id></element-citation></ref><ref id="b30-jos-2015-01578"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SR</given-names></name><name><surname>Guo</surname><given-names>SZ</given-names></name><name><surname>Kim</surname><given-names>WJ</given-names></name><name><surname>Montaner</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>Reduction of tissue plasminogen activator-induced matrix metalloproteinase-9 by simvastatin in astrocytes</article-title><source>Stroke</source><year>2006</year><volume>37</volume><fpage>1910</fpage><lpage>1912</lpage><pub-id pub-id-type="pmid">16741180</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="f1-jos-2015-01578" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Trial profile. CK, creatine kinase; LDL, low-density lipoprotein; TSH, thyroid-stimulating hormone; mITT, modified intention-to-treat population; MRI, magnetic resonance imaging; PP, per-protocol population; DWI, diffusion-weighted imaging.</p></caption><graphic xlink:href="jos-2015-01578f1"/></fig><fig id="f2-jos-2015-01578" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>New ischemic lesions on diffusion-weighted imaging in the modified intention-to-treat population (A) and per-protocol population (B).</p></caption><graphic xlink:href="jos-2015-01578f2"/></fig><table-wrap id="t1-jos-2015-01578" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Baseline characteristics of the rosuvastatin and placebo groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Rosuvastatin (n=155)</th><th align="center" valign="middle" rowspan="1" colspan="1">Placebo (n=159)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Demographics</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Sex (male)</td><td align="center" valign="top" rowspan="1" colspan="1">87 (56.1)</td><td align="center" valign="top" rowspan="1" colspan="1">101 (63.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.222</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Age (year)</td><td align="center" valign="top" rowspan="1" colspan="1">65.4 &#x000b1; 12.3</td><td align="center" valign="top" rowspan="1" colspan="1">64.6 &#x000b1; 11.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.564</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Body mass index (kg/m<sup>2</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">23.8 &#x000b1; 3.1</td><td align="center" valign="top" rowspan="1" colspan="1">24.1 &#x000b1; 3.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.417</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Abdominal circumference (cm)</td><td align="center" valign="top" rowspan="1" colspan="1">86.2 &#x000b1; 9.4</td><td align="center" valign="top" rowspan="1" colspan="1">87.2 &#x000b1; 9.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.388</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Past history</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">104 (67.0)</td><td align="center" valign="top" rowspan="1" colspan="1">102 (64.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.667</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Diabetes mellitus</td><td align="center" valign="top" rowspan="1" colspan="1">50 (32.2)</td><td align="center" valign="top" rowspan="1" colspan="1">51 (32.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hypercholesterolemia</td><td align="center" valign="top" rowspan="1" colspan="1">24 (15.4)</td><td align="center" valign="top" rowspan="1" colspan="1">26 (16.3)</td><td align="center" valign="top" rowspan="1" colspan="1">0.955</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Smoking</td><td align="center" valign="top" rowspan="1" colspan="1">72 (46.4)</td><td align="center" valign="top" rowspan="1" colspan="1">67 (42.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.512</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Coronary artery occlusive disease</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.371</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Peripheral artery occlusive disease</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.243</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Previous stroke</td><td align="center" valign="top" rowspan="1" colspan="1">16 (10.3)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.644</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Concomitant medication</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Antihypertensive</td><td align="center" valign="top" rowspan="1" colspan="1">67 (43.2)</td><td align="center" valign="top" rowspan="1" colspan="1">73 (45.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.715</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Antiplatelet</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.677</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Aspirin</td><td align="center" valign="top" rowspan="1" colspan="1">39 (25.1)</td><td align="center" valign="top" rowspan="1" colspan="1">39 (24.5)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Clopidogrel</td><td align="center" valign="top" rowspan="1" colspan="1">9 (5.8)</td><td align="center" valign="top" rowspan="1" colspan="1">10 (6.2)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Aspirin and clopidogrel</td><td align="center" valign="top" rowspan="1" colspan="1">88 (56.7)</td><td align="center" valign="top" rowspan="1" colspan="1">92 (57.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Aspirin and cilostazol</td><td align="center" valign="top" rowspan="1" colspan="1">5 (3.2)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (5.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Aspirin, clopidogrel, and cilostazol</td><td align="center" valign="top" rowspan="1" colspan="1">14 (9.0)</td><td align="center" valign="top" rowspan="1" colspan="1">9 (5.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Anticoagulant</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Lipid-lowering drug (other than statin)</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.619</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Diabetes mellitus drug</td><td align="center" valign="top" rowspan="1" colspan="1">34 (21.9)</td><td align="center" valign="top" rowspan="1" colspan="1">35 (22.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Nonsteroidal anti-inflammatory drug</td><td align="center" valign="top" rowspan="1" colspan="1">8 (5.1)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (8.1)</td><td align="center" valign="top" rowspan="1" colspan="1">0.399</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Intravenous tissue plasminogen activator</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">5 (3.1)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Log-transformed baseline diffusion-weighted imaging volume (mm<sup>3</sup>)</td><td align="center" valign="top" rowspan="1" colspan="1">6.7 &#x000b1; 1.9</td><td align="center" valign="top" rowspan="1" colspan="1">6.8 &#x000b1; 2.0</td><td align="center" valign="top" rowspan="1" colspan="1">0.761</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Baseline National Institute of Health Stroke Scale</td><td align="center" valign="top" rowspan="1" colspan="1">3 [1-6]</td><td align="center" valign="top" rowspan="1" colspan="1">3 [2-5.3]</td><td align="center" valign="top" rowspan="1" colspan="1">0.713</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Degree of stenosis</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1">0.703</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;No stenosis</td><td align="center" valign="top" rowspan="1" colspan="1">12 (7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (8.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x0003c; 50%</td><td align="center" valign="top" rowspan="1" colspan="1">52 (36.4)</td><td align="center" valign="top" rowspan="1" colspan="1">56 (38.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;50%-99%</td><td align="center" valign="top" rowspan="1" colspan="1">47 (32.9)</td><td align="center" valign="top" rowspan="1" colspan="1">53 (36.6)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Occlusion</td><td align="center" valign="top" rowspan="1" colspan="1">44 (30.8)</td><td align="center" valign="top" rowspan="1" colspan="1">36 (24.8)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lab</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;White blood cells (&#x000d7; 10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="top" rowspan="1" colspan="1">7.96 &#x000b1; 89.2</td><td align="center" valign="top" rowspan="1" colspan="1">7.48 &#x000b1; 84.3</td><td align="center" valign="top" rowspan="1" colspan="1">0.929</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Neutrophils (&#x000d7; 10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="top" rowspan="1" colspan="1">6.24 &#x000b1; 1.6</td><td align="center" valign="top" rowspan="1" colspan="1">6.13 &#x000b1; 1.74</td><td align="center" valign="top" rowspan="1" colspan="1">0.616</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hemoglobin (g/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">14 &#x000b1; 1.6</td><td align="center" valign="top" rowspan="1" colspan="1">14 &#x000b1; 1.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.823</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hematocrit (%)</td><td align="center" valign="top" rowspan="1" colspan="1">41 &#x000b1; 4.5</td><td align="center" valign="top" rowspan="1" colspan="1">41.1 &#x000b1; 4.4</td><td align="center" valign="top" rowspan="1" colspan="1">0.817</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Platelet count (&#x000d7; 10<sup>3</sup>/&#x003bc;L)</td><td align="center" valign="top" rowspan="1" colspan="1">246.3 &#x000b1; 60.3</td><td align="center" valign="top" rowspan="1" colspan="1">240.1 &#x000b1; 65.5</td><td align="center" valign="top" rowspan="1" colspan="1">0.296</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Blood urea nitrogen (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">15.1 &#x000b1; 5.2</td><td align="center" valign="top" rowspan="1" colspan="1">15.5 &#x000b1; 5.6</td><td align="center" valign="top" rowspan="1" colspan="1">0.575</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Creatinine (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">0.83 &#x000b1; 0.208</td><td align="center" valign="top" rowspan="1" colspan="1">0.865 &#x000b1; 0.253</td><td align="center" valign="top" rowspan="1" colspan="1">0.244</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Fasting glucose (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">131.2 &#x000b1; 57.8</td><td align="center" valign="top" rowspan="1" colspan="1">136.8 &#x000b1; 57.1</td><td align="center" valign="top" rowspan="1" colspan="1">0.256</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Albumin (g/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">4.1 &#x000b1; 0.34</td><td align="center" valign="top" rowspan="1" colspan="1">4.14 &#x000b1; 0.36</td><td align="center" valign="top" rowspan="1" colspan="1">0.302</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Uric acid (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">5.06 &#x000b1; 1.36</td><td align="center" valign="top" rowspan="1" colspan="1">5.06 &#x000b1; 1.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.770</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;high sensitivity C-reactive protein (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">2.517 &#x000b1; 7.111</td><td align="center" valign="top" rowspan="1" colspan="1">2.114 &#x000b1; 6.794</td><td align="center" valign="top" rowspan="1" colspan="1">0.491</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Uric acid (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">5.06 &#x000b1; 1.36</td><td align="center" valign="top" rowspan="1" colspan="1">5.06 &#x000b1; 1.53</td><td align="center" valign="top" rowspan="1" colspan="1">0.770</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;high sensitivity C-reactive protein (mg/dL)</td><td align="center" valign="top" rowspan="1" colspan="1">2.517 &#x000b1; 7.111</td><td align="center" valign="top" rowspan="1" colspan="1">2.114 &#x000b1; 6.794</td><td align="center" valign="top" rowspan="1" colspan="1">0.491</td></tr></tbody></table><table-wrap-foot><fn><p>Values are number (%), mean&#x000b1;standard deviation, or median [interquartile range].</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2-jos-2015-01578" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Adverse events</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Rosuvastatin (n=155)</th><th align="center" valign="middle" rowspan="1" colspan="1">Placebo (n=159)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Any AE</td><td align="center" valign="top" rowspan="1" colspan="1">88 (56.8)</td><td align="center" valign="top" rowspan="1" colspan="1">87 (54.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any SAE</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2.6)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (5.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.379</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;SAE in nervous system</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.3)</td><td align="center" valign="top" rowspan="1" colspan="1">8 (5.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.104</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Progression or clinical recurrence of stroke<sup><xref rid="tfn1-jos-2015-01578" ref-type="table-fn">*</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">7 (4.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.067</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Brain herniation</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Intracerebral hemorrhage</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.494</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;SAE in cardiac system</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.2)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.619</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Atrial fibrillation</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.494</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Chest discomfort</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Myocardial infarction</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.494</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;SAE in gastrointestinal system</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Upper gastrointestinal bleeding</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.6)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any AE resulting in discontinuation of study drug</td><td align="center" valign="top" rowspan="1" colspan="1">5 (2.1)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.539</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any AE with incidence of &#x02265; 5%</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Constipation</td><td align="center" valign="top" rowspan="1" colspan="1">13 (8.4)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.726</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Headache</td><td align="center" valign="top" rowspan="1" colspan="1">9 (5.8)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (9.4)</td><td align="center" valign="top" rowspan="1" colspan="1">0.319</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Progression or clinical recurrence of stroke<sup><xref rid="tfn2-jos-2015-01578" ref-type="table-fn">&#x02020;</xref></sup></td><td align="center" valign="top" rowspan="1" colspan="1">11 (7.1)</td><td align="center" valign="top" rowspan="1" colspan="1">13 (8.2)</td><td align="center" valign="top" rowspan="1" colspan="1">0.883</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Coronary artery occlusive disease</td><td align="center" valign="top" rowspan="1" colspan="1">16 (10.3)</td><td align="center" valign="top" rowspan="1" colspan="1">12 (7.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.506</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Hypertension</td><td align="center" valign="top" rowspan="1" colspan="1">12 (7.7)</td><td align="center" valign="top" rowspan="1" colspan="1">14 (8.8)</td><td align="center" valign="top" rowspan="1" colspan="1">0.891</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Musculoskeletal AE</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Myalgia</td><td align="center" valign="top" rowspan="1" colspan="1">3 (1.9)</td><td align="center" valign="top" rowspan="1" colspan="1">4 (2.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Myopathy</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Rhabdomyolysis</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Laboratory values</td><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;CK elevation &#x0003e;3&#x000d7;ULN</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;Aspartate aminotransferase or alanine aminotransferase elevation &#x0003e;3&#x000d7;ULN</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Death</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.4)</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.5)</td><td align="center" valign="top" rowspan="1" colspan="1">1.000</td></tr></tbody></table><table-wrap-foot><fn><p>Values are number (%).</p></fn><fn id="tfn1-jos-2015-01578"><label>*</label><p>Two patients with clinical recurrent stroke were included;</p></fn><fn id="tfn2-jos-2015-01578"><label>&#x02020;</label><p>Three patients with clinical recurrent stroke (including two patients reported in SAE) were included.</p></fn><fn><p>AE, adverse event; SAE, serious adverse event; CK, creatine kinase; ULN, upper limit of the normal range.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3-jos-2015-01578" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Occurrence of intracranial hemorrhagic transformation on gradient-recalled echo (GRE)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" rowspan="1" colspan="1"/><th align="center" valign="middle" rowspan="1" colspan="1">Rosuvastatin (n = 137)</th><th align="center" valign="middle" rowspan="1" colspan="1">Placebo (n = 152)</th><th align="center" valign="middle" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">HI1</td><td align="center" valign="top" rowspan="1" colspan="1">2 (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">15 (9.9)</td><td align="center" valign="top" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">HI2</td><td align="center" valign="top" rowspan="1" colspan="1">2<sup><xref rid="tfn3-jos-2015-01578" ref-type="table-fn">*</xref></sup> (1.4)</td><td align="center" valign="top" rowspan="1" colspan="1">7<sup><xref rid="tfn4-jos-2015-01578" ref-type="table-fn">&#x02020;</xref></sup> (4.6)</td><td align="center" valign="top" rowspan="1" colspan="1">0.177</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PH1</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.478</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PH2</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Radiological subarachnoid hemorrhage</td><td align="center" valign="top" rowspan="1" colspan="1">1 (0.7)</td><td align="center" valign="top" rowspan="1" colspan="1">0 (0.0)</td><td align="center" valign="top" rowspan="1" colspan="1">0.478</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Any hemorrhagic transformation</td><td align="center" valign="top" rowspan="1" colspan="1">6 (4.3)</td><td align="center" valign="top" rowspan="1" colspan="1">22 (14.5)</td><td align="center" valign="top" rowspan="1" colspan="1">0.007</td></tr></tbody></table><table-wrap-foot><fn><p>Values are number (%).</p><p>Hemorrhagic transformation was categorized into small petechial hemorrhagic infarction (HI1), confluent petechial HI (HI2), small parenchymal hemorrhage (PH1, &#x0003c;30% of infarct, mild mass effect), and large PH (PH2, &#x0003e;30% of infarct, marked mass effect).[<xref rid="b17-jos-2015-01578" ref-type="bibr">17</xref>]</p></fn><fn id="tfn3-jos-2015-01578"><label>*</label><p>including 1 patient who had HI-1 on baseline GRE and HI-2 on follow-up GRE.</p></fn><fn id="tfn4-jos-2015-01578"><label>&#x02020;</label><p>including 1 patient who had HI-1 on baseline GRE and HI-2 on follow-up GRE, 4 patients who had HI-1 on 5-day GRE and HI-2 on 14-day GRE.</p></fn></table-wrap-foot></table-wrap></floats-group></article>